申请人:Hoffmann-La Roche Inc.
公开号:US06417360B1
公开(公告)日:2002-07-09
The compounds of formula (I)
wherein R1 has the significance as given in the description, are inhibitors of endothelin receptors and can therefore be used for the treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction.
式(I)中R1具有描述中给出的含义的化合物是内皮素受体的抑制剂,因此可用于治疗与异常血管张力和内皮功能障碍相关的疾病。